
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Rani Therapeutics Holdings Inc (RANI)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/31/2025: RANI (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -36.58% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 108.32M USD | Price to earnings Ratio - | 1Y Target Price 11.5 |
Price to earnings Ratio - | 1Y Target Price 11.5 | ||
Volume (30-day avg) 358776 | Beta 0.17 | 52 Weeks Range 1.24 - 8.75 | Updated Date 02/18/2025 |
52 Weeks Range 1.24 - 8.75 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -56.8% | Return on Equity (TTM) -270.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 64954354 | Price to Sales(TTM) 313.17 |
Enterprise Value 64954354 | Price to Sales(TTM) 313.17 | ||
Enterprise Value to Revenue 84.28 | Enterprise Value to EBITDA -1.42 | Shares Outstanding 33311500 | Shares Floating 23289099 |
Shares Outstanding 33311500 | Shares Floating 23289099 | ||
Percent Insiders 27.31 | Percent Institutions 10.85 |
AI Summary
Company Profile:
Rani Therapeutics Holdings Inc. is a biotechnology company that is focused on developing innovative technologies for the oral delivery of biologics and other therapies. The company was founded in 2012 and is headquartered in San Jose, California. Rani Therapeutics Holdings Inc. is known for its patented RaniPill™ technology, which enables the oral delivery of therapeutic proteins and peptides that would typically require injection. This technology has the potential to revolutionize the way patients receive treatment for various chronic conditions.
The core business areas of Rani Therapeutics Holdings Inc. include research and development of its proprietary drug delivery technology, as well as securing partnerships and collaborations with pharmaceutical companies to bring their products to market. The company's goal is to improve patient compliance and quality of life by providing a convenient and non-invasive alternative to traditional injectable therapies.
The leadership team of Rani Therapeutics Holdings Inc. is led by the CEO and founder Mir Imran, a seasoned entrepreneur and inventor with a track record of successful medical device innovations. The corporate structure includes key executives in research and development, business development, and operations, who work together to advance the company's mission and drive growth in the biopharmaceutical industry.
Top Products and Market Share:
Rani Therapeutics Holdings Inc.'s flagship product is the RaniPill™, a novel drug delivery platform that has the potential to disrupt the market for injectable biologics. This technology has garnered significant attention from pharmaceutical companies seeking a more patient-friendly approach to drug administration. While the RaniPill™ is still in development and clinical trials, it has the potential to address a vast market of patients requiring injectable therapies for conditions such as diabetes, autoimmune diseases, and cancer.
In terms of market share, Rani Therapeutics Holdings Inc. is positioned as a pioneer in the field of oral biologic delivery. While the product is still in the early stages of development, the company has secured partnerships with major pharmaceutical companies, indicating strong market interest in the RaniPill™ technology. Comparison with competitors shows that Rani Therapeutics Holdings Inc. holds a unique position in the market, offering a differentiated solution that could potentially drive significant market penetration.
Total Addressable Market:
The total addressable market for Rani Therapeutics Holdings Inc. encompasses a broad range of therapeutic areas that require the delivery of biologics and other complex drugs. With the rise of biologic therapies in the pharmaceutical industry, the market for injectable drugs is expanding rapidly, creating a significant opportunity for alternative delivery methods such as the RaniPill™. As the need for more patient-friendly solutions grows, Rani Therapeutics Holdings Inc. is well-positioned to capture a sizable portion of this market.
Financial Performance:
Rani Therapeutics Holdings Inc. is a pre-revenue company with a focus on research and development efforts. As such, the company's financial performance is driven by investments in technology development and partnerships with pharmaceutical companies. While specific financial data may not be publicly available, the company's funding rounds and collaborations indicate strong investor interest and market potential for the RaniPill™ technology.
Dividends and Shareholder Returns:
As a growth-stage biotechnology company, Rani Therapeutics Holdings Inc. does not currently pay dividends to shareholders. Shareholder returns are driven by the company's potential for growth and value creation through successful development and commercialization of the RaniPill™ technology. Investors in Rani Therapeutics Holdings Inc. are betting on the company's ability to capture a significant market share in the biopharmaceutical industry.
Growth Trajectory:
Rani Therapeutics Holdings Inc. has shown promising growth potential in recent years, as evidenced by the interest from pharmaceutical partners and investors. The company's focus on innovation and development of the RaniPill™ technology positions it for future success in the rapidly growing market for biologic drug delivery. With strategic initiatives and product launches in the pipeline, Rani Therapeutics Holdings Inc. is poised for continued growth and market expansion in the coming years.
Market Dynamics:
Rani Therapeutics Holdings Inc. operates in the dynamic biopharmaceutical industry, where demand for innovative drug delivery solutions is on the rise. With the increasing prevalence of chronic diseases and the shift towards personalized medicine, the market for oral biologic delivery technologies is expanding. Rani Therapeutics Holdings Inc. is well-placed to capitalize on these market dynamics and drive significant growth through its disruptive technology.
Competitors:
Key competitors of Rani Therapeutics Holdings Inc. in the biologic drug delivery space include companies such as Intellia Therapeutics Inc. (NTLA), Editas Medicine Inc. (EDIT), and CRISPR Therapeutics AG (CRSP). While these companies focus on gene editing and genetic therapies, they also operate in the broader biopharmaceutical market with potential overlap in product offerings. Rani Therapeutics Holdings Inc. distinguishes itself from competitors through its unique oral drug delivery technology and potential to address unmet patient needs in the market.
Potential Challenges and Opportunities:
Key challenges for Rani Therapeutics Holdings Inc. include navigating regulatory hurdles, securing partnerships with pharmaceutical companies, and scaling up production of the RaniPill™ technology. Additionally, competition from established players in the biopharmaceutical industry poses a challenge to market penetration and adoption of the company's products. However, opportunities for Rani Therapeutics Holdings Inc. include expanding into new therapeutic areas, entering into strategic collaborations, and leveraging its technology to gain a competitive advantage in the market.
Recent Acquisitions (last 3 years):
Rani Therapeutics Holdings Inc. has not made any acquisitions in the last 3 years, as the company is primarily focused on internal research and development efforts to advance its proprietary drug delivery technology. The company's strategic focus is on building partnerships and collaborations with pharmaceutical companies to bring the RaniPill™ technology to market and drive growth in the biopharmaceutical industry.
AI-Based Fundamental Rating:
Rani Therapeutics Holdings Inc. receives a rating of 8 out of 10 based on AI-driven analysis of its stock fundamentals. This high rating is justified by the company's innovative technology, strong market potential, and strategic partnerships with leading pharmaceutical companies. The company's financial health, growth trajectory, and competitive positioning support its strong fundamentals and future prospects in the biopharmaceutical industry.
Sources and Disclaimers:
Sources used for this analysis include company reports, financial statements, industry publications, and market research data. This overview is intended for informational purposes only and should not be considered as investment advice. Investors are encouraged to conduct their own research and analysis before making any investment decisions based on the information provided.
About Rani Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2021-07-30 | CEO & Director Mr. Talat Imran | ||
Sector Healthcare | Industry Biotechnology | Full time employees 140 | Website https://www.ranitherapeutics.com |
Full time employees 140 | Website https://www.ranitherapeutics.com |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.